GHRP-6 potential benefits and areas of research

GHRP-6's demonstrated benefit is a large, dose-dependent, reproducible release of the body's own growth hormone. In the study that established it, 18 healthy men given intravenous doses of 0.1, 0.3 and 1.0 µg/kg reached mean peak serum GH of 7.6, 16.5 and 68.7 µg/L respectively, against 1.2 µg/L on placebo (Bowers et al., J Clin Endocrinol Metab 1990). That is a genuinely large effect — a roughly 57-fold rise over placebo at the top dose. What has never been measured in a published trial is what that GH does: no study has used muscle, fat, strength, recovery or sleep as an endpoint for this compound.

The 1990 study is worth reading in detail because almost everything written about GHRP-6 traces back to it, and it is more careful than its reputation suggests.

• Design. The synthetic hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ was given by intravenous bolus at three doses to 18 normal men, and compared directly against GHRH(1-44)-NH₂ at 1.0 µg/kg.

• Specificity check. Serum prolactin, LH, TSH and cortisol were measured alongside. Prolactin and cortisol rose about two-fold above baseline only at the highest 1 µg/kg dose; LH and TSH did not change over the first hour.

• Synergy. Submaximal GHRP-6 doses of 0.1 and 0.3 µg/kg given together with 1 µg/kg GHRH stimulated GH release synergistically — the finding that showed the two peptides act through independent systems.

• Tolerability. No adverse clinical effects or laboratory abnormalities were observed in response to GHRP-6. The mild facial flushing reported in the paper — in 16 of the 18 men — followed GHRH, not GHRP-6.

That last detail is worth flagging, because GHRP-6 is often described as causing flushing. In the study that people cite for it, the flushing belonged to the comparator.

The authors closed by proposing that GHRP-6's activity "reflects a new physiological system in need of further characterization." They were right. A synthetic peptide with no structural homology to GHRH, acting potently through its own receptor, strongly implied that a natural ligand for that receptor existed and had not yet been found. The receptor was cloned within a few years, and in 1999 the missing ligand was purified from rat stomach: a 28-amino-acid acylated peptide its discoverers named ghrelin, after the Proto-Indo-European root meaning "grow" (Kojima et al., Nature 1999). GHRP-6 is the molecular tool that led there.

Class reviews written before that discovery describe GHRP-6 as "the first hexapeptide studied extensively in humans," with GH-releasing activity that is marked, dose-related and reproducible after intravenous, subcutaneous, intranasal and even oral administration, synergistic with GHRH, and only partially blunted by influences — glucose, free fatty acids, glucocorticoids, exogenous somatostatin — that nearly abolish the response to GHRH alone (Ghigo et al., Eur J Endocrinol 1997). That robustness is a real pharmacological advantage over a GHRH analogue, and it is separate from any claim about benefit.

GHRP-6's reputation for causing intense hunger is the most-repeated claim about it, and the mechanism is sound: it agonises the growth hormone secretagogue receptor, which is ghrelin's receptor, and ghrelin signals hunger.

The controlled human measurement, though, was done with GHRP-2, not GHRP-6. Seven lean healthy men on a subcutaneous GHRP-2 infusion ate 35.9 ± 10.9% more at a buffet meal than on saline, with no change in macronutrient selection (Laferrère et al., J Clin Endocrinol Metab 2005). Applying that number to GHRP-6 is a reasonable inference from shared mechanism — but it is an inference, and the honest phrasing is that appetite stimulation is expected from the receptor rather than demonstrated for this molecule in a published human trial.

• GHRP-2 — the better-documented successor. Same receptor, a validated diagnostic role in Japan, a 30-day dosing study, and the measured appetite data.

• Hexarelin — more potent, but with clearly demonstrated attenuation of the GH response over weeks and a separate cardiac receptor interaction.

• Ipamorelin — roughly as potent as GHRP-6 in the original characterisation, but selected specifically for not raising ACTH, cortisol or prolactin. Its whole rationale is to be GHRP-6 without GHRP-6's hormonal spillover.

• GHRH analogues — a different receptor, which is why they are combined with a GHRP rather than substituted for one.

GHRP-6 is prohibited in sport at all times under WADA section S2. Unlike its siblings it is excreted largely unchanged, and has been detected in urine 23 hours after administration (Semenistaya et al., Drug Test Anal 2015).

See also GHRP-6 side effects and dosing education.